LOS ANGELES--(BUSINESS WIRE)--
Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of Johnson & Johnson (“J&J” or the “Company”) (NYSE: JNJ) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the J&J investigation page on our website at www.glancylaw.com/case/johnson-johnson.
On February 5, 2018, CNBC published an article stating that “court proceedings could expose potentially damaging documents” related to J&J’s talc products, such as Johnson’s Baby Powder. On this news, shares of J&J fell $7.29 per share or more than 5%, to close at $130.39 on February 5, 2018.
Then, on February 7, 2018, the Beasley Allen Law Firm issued a press release stating that “[l]awsuits filed by ovarian cancer and mesothelioma victims are revealing never-before-seen documents from Johnson & Johnson and talc supplier, Imerys, that shed light on just how prevalent asbestos and heavy metals are in the talc used in Baby Powder.” The release stated that “[i]nternal Johnson & Johnson documents from 1972 note that asbestos was found in 100 percent of talc samples tested at the time, but this information was never released publicly.” It further stated that J&J stopped funding a project designed to test talc samples for asbestos contamination once a majority of the sample batches were found to be positive for asbestos. On this news, shares of J&J fell $5.06 per share, to close at $126.36 per share on February 8, 2018, thereby further injuring investors.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased J&J securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180215006440/en/
